Omega Therapeutics

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Our mission is to develop innovative treatments and diagnostics to prevent, diagnose and treat life-threatening illnesses and to make them accessible and affordable to all.

Our vision is to be the most trusted and respected biotechnology company, pioneering the development of effective treatments for serious health problems.

Omega Therapeutics has been recognized by numerous awards, including the prestigious “Innovative Technology Award” from the National Institutes of Health, and has received multiple grants from governmental and non-governmental organizations.